Metformin er 500
Searched over 200M research papers
Summary
10 papers analyzed
These studies suggest that metformin ER 500 mg is effective and well-tolerated for glycemic control in type 2 diabetes, with benefits in adherence and satisfaction, and is bioequivalent when combined with other medications.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Metformin ER 500 mg: Efficacy, Adherence, and Bioequivalence
Efficacy of Metformin ER 500 mg in Type 2 Diabetes
Metformin extended-release (ER) 500 mg has been shown to effectively lower fasting plasma glucose and glycated hemoglobin (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM). In a 14-week, multicenter, double-blind, dose-response study, patients receiving metformin ER 500 mg daily experienced significant improvements in glucose variables compared to placebo. The adjusted mean changes in fasting plasma glucose from baseline exceeded those associated with placebo by 19 to 84 mg/dL, and the differences in HbA1c ranged from 0.6% to 2.0% at dosages of 500 to 2000 mg daily. These findings indicate that even the lowest dose of metformin ER can provide substantial glycemic control.
Patient Adherence and Satisfaction with Metformin ER 500 mg
A postmarketing observational study in India compared patient adherence, satisfaction, and experience with metformin 500 mg prolonged release (PR) tablets to metformin 500 mg ER tablets. The study found that the PR formulation was more acceptable due to its smaller size, ease of swallowing, and lack of aftertaste. The ghost pill effect was significantly lower in the PR group (0.7%) compared to the ER group (8.5%). Overall, more than 60% of patients reported being comfortable, satisfied, and experiencing a positive effect on their well-being with the PR formulation. This suggests that the PR formulation may improve adherence and patient satisfaction compared to the ER formulation.
Bioequivalence of Metformin ER 500 mg
Several studies have demonstrated the bioequivalence of metformin ER 500 mg when combined with other medications. For instance, a study comparing a fixed-dose combination (FDC) of atorvastatin and metformin ER 500 mg to the concurrent administration of individual formulations found that the FDC had similar bioavailability and safety profiles to the separate components. The 90% confidence intervals for the pharmacokinetic parameters were within the bioequivalence acceptance criteria of 80-125% . Another study confirmed the bioequivalence of metformin in ertugliflozin/metformin FDC tablets to Canadian-sourced metformin coadministered with ertugliflozin under both fasted and fed conditions . These findings support the use of metformin ER 500 mg in combination therapies to reduce pill burden and enhance patient compliance.
Conclusion
Metformin ER 500 mg is an effective and well-tolerated option for managing type 2 diabetes. It provides significant improvements in glycemic control, and its prolonged-release formulation may enhance patient adherence and satisfaction. Additionally, metformin ER 500 mg has been shown to be bioequivalent to other formulations when used in combination therapies, making it a versatile option for comprehensive diabetes management.
Sources and full results
Most relevant research papers on this topic
